Frazier Life Sciences Management L.P. lifted its stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) by 58.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,892,547 shares of the company's stock after buying an additional 697,368 shares during the period. Frazier Life Sciences Management L.P. owned approximately 3.34% of Design Therapeutics worth $10,182,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of DSGN. Barclays PLC lifted its stake in shares of Design Therapeutics by 34.2% in the third quarter. Barclays PLC now owns 96,635 shares of the company's stock worth $520,000 after acquiring an additional 24,602 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of Design Therapeutics by 61.6% in the third quarter. Point72 Asset Management L.P. now owns 1,600,740 shares of the company's stock worth $8,612,000 after acquiring an additional 609,939 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in shares of Design Therapeutics by 2.9% in the third quarter. Baker BROS. Advisors LP now owns 1,743,725 shares of the company's stock worth $9,381,000 after acquiring an additional 48,431 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of Design Therapeutics in the third quarter worth about $64,000. Finally, PDT Partners LLC lifted its stake in shares of Design Therapeutics by 33.1% in the third quarter. PDT Partners LLC now owns 36,099 shares of the company's stock worth $194,000 after acquiring an additional 8,972 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company's stock.
Design Therapeutics Stock Performance
Shares of NASDAQ:DSGN traded up $0.11 during trading on Tuesday, hitting $6.62. The company's stock had a trading volume of 150,711 shares, compared to its average volume of 234,029. Design Therapeutics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $7.77. The stock's 50-day moving average price is $5.66 and its two-hundred day moving average price is $4.86. The company has a market capitalization of $374.83 million, a PE ratio of -7.82 and a beta of 1.86.
About Design Therapeutics
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Read More
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
